semaglutide alzheimer's clinical trial David Standaert, M.D., Ph.D., was recently featured in @sciencenewsmagazine discussing recent findings from two large trials testing whether the GLP‑1 drug semaglutide, taken as an oral pill, could slow the progression Semaglutide's Alzheimer's Trial Failure: Rethinking

Subsequent trials, including AWARD-10 and SUSTAIN-9, further confirmed the efficacy of intensification strategies, demonstrating meaningful improvements in glycemic control and body weight when one class is added to the other [31, 32]

Lancet 396 , 12231249 (2020)

Its essential to note that Semaglutide GLP-1 is most effective when its combined with a healthy diet and consistent physical activity

participants receive guidance from health coaches, many of whom have completed the program themselves

However analysis of the research yet to be published has revealed the proportional reduction in such events holds regardless of participants starting weight